ClinicalTrials.gg
CompletedNCT06534411REIMAGINE 5Updated Oct 19, 2026

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both

A Phase 3 interventional study of Cagrilintide and Semaglutide in Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 163 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,023
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing cagrilintide in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, 4 of them phase 3. cagrilintide · Diabetes Mellitus, Type 2.

Enrollment
5th of 15
1,023 · median 274
Started
2024
with 5 others
Phase 3
10 of 15
3 open now
Registered
9th of 15
by date
Lead sponsor
15 of 15
Novo Nordisk A/S

Among the 15 studies testing cagrilintide in Diabetes Mellitus, Type 2, this one is the 5th largest by enrollment, is one of 6 that started in 2024, is one of 10 in phase 3, and was the 9th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 15 studies testing cagrilintide in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About cagrilintide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing cagrilintide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This study will look at how much CagriSema lowers blood sugar and body weight in people with type 2 diabetes. CagriSema is a new investigational medicine. Doctors cannot yet prescribe CagriSema. CagriSema will be compared to a medicine called tirzepatide. Doctors can prescribe tirzepatide in some countries. Participants will either receive CagriSema or tirzepatide. Which treatment the participant will receive is decided by chance. For each participant, the study will last for up to 1 year and 4 months.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female (sex at birth).
  • Age 18 years or above at the time of signing the .
  • Diagnosed with type 2 diabetes mellitus greater than or equal to (>=) 180 days before screening.
  • Stable daily dose(s) >= 90 days before screening of any of the following antidiabetic drug(s) or combination regimen(s) at effective or maximum tolerated dose as judged by the investigator:
  • Metformin
  • sodium-glucose co-transporter 2 inhibitor (SGLT2i)
  • (HbA1c) 7.0-10.5 percent (53-91 millimoles per mol [mmol/mol]) (both inclusive) as determined by central laboratory at screening.
  • (BMI) >= 30 kilogram per square meter (kg/m\^2) at screening. BMI will be calculated in the electronic case report form (eCRF) based on height and body weight at screening.

Exclusion criteria

Exclusion Criteria:

  • Female who is pregnant, breast-feeding or intends to become pregnant or is of and not using a highly effective method.
  • Renal impairment with estimated less than \< 30 milliliter per minute per 1.73 square meter (mL/min/1.73 m\^2) as determined by central laboratory at screening.
  • Treatment with any anti-diabetic or anti-obesity medication (irrespective of indication) other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days is allowed.
  • Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by an eye examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,023 participants (actual)

Study arms

  • Experimental
    CagriSema

    Participants will receive once-weekly subcutaneous (s.c) injections of CagriSema (cagrilintide and semaglutide) at escalating doses every 4 weeks in a 8-week dose escalation period until target dose of CagriSema is achieved and maintained for 52 weeks.

    Drug: Cagrilintide · Drug: Semaglutide

  • Experimental
    Tirzepatide

    Participants will receive once-weekly s.c injections of tirzepatide at escalating dose in a 4-week dose escalating period and maintained up to 56 weeks.

    Drug: Tirzepatide

Interventions

  • Participants will receive once-weekly cagrilintide subcutaneously.

  • Participants will receive once-weekly semaglutide subcutaneously.

  • Participants will receive once-weekly tirzepatide subcutaneously.

06

What researchers measure

Primary outcomes

  1. Change in Glycated Haemoglobin (HbA1c)

    Measured in percentage points.

    Time frame: From baseline (week 0) to end of treatment (week 60)

  2. Relative Change in Body Weight

    Measured in percentage (%).

    Time frame: From baseline (week 0) to end of treatment (week 60)

Secondary outcomes

  1. Change in HbA1c

    Measured in percentage points.

    Time frame: From baseline (week 0) to end of treatment (week 60)

  2. Change in Fasting Plasma Glucose (FPG)

    Measured as millimole per liter (mmol/L).

    Time frame: From baseline (week 0) to end of treatment (week 60)

  3. Number of Participants Who Achieve HbA1c Target Values of Less Than (<) 7.0 (Percent [%]) (< 53 millimole per mole [mmol/mol])

    Measured as count of participants.

    Time frame: At end of treatment (week 60)

  4. Number of Participants Who Achieve HbA1c Target Values of Less Than or Equal to (<=) 6.5% (<= 48 mmol/mol)

    Measured as count of participants.

    Time frame: At end of treatment (week 60)

  5. Number of Participants Who Achieve Greater Than or Equal to (>=) 5% Weight Reduction

    Measured as count of participants.

    Time frame: From baseline (week 0) to end of treatment (week 60)

  6. Number of Participants Who Achieve >= 10% Weight Reduction

    Measured as count of participants.

    Time frame: From baseline (week 0) to end of treatment (week 60)

  7. Number of Participants Who Achieve >= 15% Weight Reduction

    Measured as count of participants.

    Time frame: From baseline (week 0) to end of treatment (week 60)

  8. Number of Participants Who Achieve >= 20% Weight Reduction

    Measured as count of participants.

    Time frame: From baseline (week 0) to end of treatment (week 60)

  9. Change in Systolic Blood Pressure (SBP)

    Measured in millimeter of mercury (mmHg).

    Time frame: From baseline (week 0) to end of treatment (week 60)

  10. Change in Diastolic Blood Pressure (DBP)

    Measured in mmHg.

    Time frame: From baseline (week 0) to end of treatment (week 60)

  11. Change in Waist Circumference

    Measured in centimeter (cm).

    Time frame: From baseline (week 0) to end of treatment (week 60)

  12. Ratio to Baseline in Lipids: Total Cholesterol

    Measured as ratio.

    Time frame: From baseline (week 0) to end of treatment (week 60)

  13. Ratio to Baseline in Lipids: High Density Lipoprotein (HDL) Cholesterol

    Measured as ratio.

    Time frame: From baseline (week 0) to end of treatment (week 60)

  14. Ratio to Baseline in Lipids: Low Density Lipoprotein (LDL) Cholesterol

    Measured as ratio.

    Time frame: From baseline (week 0) to end of treatment (week 60)

  15. Ratio to Baseline in Lipids: Very Low Density Lipoprotein (VLDL) Cholesterol

    Measured as ratio.

    Time frame: From baseline (week 0) to end of treatment (week 60)

  16. Ratio to Baseline in Lipids: Triglycerides

    Measured as ratio.

    Time frame: From baseline (week 0) to end of treatment (week 60)

  17. Ratio to Baseline in Lipids: Non-HDL cholesterol

    Measured as ratio.

    Time frame: From baseline (week 0) to end of treatment (week 60)

  18. Change in Short Form (SF) -36v2 Score: Physical Component Summary Score

    Measured as score points. SF-36v2 Acute measures Health-Related Quality of Life (HRQOL). The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2. Acute scores are norm-based scores, i.e. transformed to a scale where the 2009 US general population has a mean of 50 and a standard deviation of 10. Physical component summary scores ranges from 6.1 to 79.7 with higher scores indicating better functional health and well-being.

    Time frame: From baseline (week 0) to end of treatment (week 60)

  19. Change in SF-36v2 Score: Mental Component Summary Score

    Measured as score points. SF-36v2 Acute measures Health-Related Quality of Life (HRQOL). The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2. Acute scores are norm-based scores, i.e. transformed to a scale where the 2009 US general population has a mean of 50 and a standard deviation of 10. Mental component summary scores ranges from -3.8 to 78.7 with higher scores indicating better functional health and well-being.

    Time frame: From baseline (week 0) to end of treatment (week 60)

  20. Change in SF-36v2 Score: Vitality Subscale

    Measured as score points. SF-36v2 Acute measures Health-Related Quality of Life (HRQOL). The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2. Acute scores are norm-based scores, i.e. transformed to a scale where the 2009 US general population has a mean of 50 and a standard deviation of 10. Vitality score ranges from 25.6 to 69.1 with higher scores indicating better functional health and well-being.

    Time frame: From baseline (week 0) to end of treatment (week 60)

  21. Change in Impact of Weight on Quality of Life Lite for Clinical Trials Version (IWQOL-Lite-CT) : Physical Function score

    Measured as score points. IWQOL-Lite-CT measures weight-related physical and psychosocial functioning. The measure consists of 20 items yielding 3 composite scores, and 1 total score. Higher scores indicate better levels of functioning. Physical functioning score ranges from 0 to 100, with higher scores reflecting better levels of functioning.

    Time frame: From baseline (week 0) to end of treatment (week 60)

  22. Change in IWQOL-Lite-CT: Total score

    Measured as score points. IWQOL-Lite-CT measures weight-related physical and psychosocial functioning. The measure consists of 20 items yielding 3 composite scores, and 1 total score. Higher scores indicate better levels of functioning. Total score ranges from 0 to 100, with higher scores reflecting better levels of functioning.

    Time frame: From baseline (week 0) to end of treatment (week 60)

  23. Number of Treatment Emergent Adverse Events (TEAEs)

    Measured as count of events.

    Time frame: From baseline (week 0) to end of study (week 66)

  24. Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (<54 Milligram per Deciliter [mg/dL]), Confirmed by Blood Glucose (BG) Meter

    Measured as count of episodes.

    Time frame: From baseline (week 0) to end of study (week 66)

  25. Number of Severe Hypoglycaemic Episodes (Level 3): Hypoglycaemia Associated With Severe Cognitive Impairment Requiring External Assistance for Recovery, With no Specific Glucose Threshold

    Measured as count of episodes.

    Time frame: From baseline (week 0) to end of study (week 66)

07

Study locations

163 sites
  • Cahaba Research
    Pelham, Alabama 35124, United States
  • Velocity Clinical Research-Phoenix
    Phoenix, Arizona 85006, United States
  • AES Tucson DRS
    Tucson, Arizona 85712, United States
  • Woodland Int. Research Group
    Little Rock, Arkansas 72211, United States
  • Velocity Clin Res-Chula Vista
    Chula Vista, California 91911, United States
  • John Muir Physicians Network
    Concord, California 94520, United States
  • Diabetes & Endocrine Specialists - La Mesa
    La Mesa, California 91942, United States
  • Velocity Clin Research LA
    Los Angeles, California 90017, United States
  • Desert Oasis Healthcare
    Palm Springs, California 92262, United States
  • Velocity Clin Res Santa Ana
    Santa Ana, California 92704, United States
  • Velocity Clin Res - Panorama
    Van Nuys, California 91405, United States
  • Optumcare Clinical Trials,LLC-Golden
    Colorado Springs, Colorado 80906, United States
  • FEME Medical LLC
    Washington D.C., District of Columbia 20010, United States
  • Tampa Bay Medical Research
    Clearwater, Florida 33761, United States
  • AGA Clinical Trial
    Hialeah, Florida 33012, United States
  • Bioclinical Research Alliance
    Miami, Florida 33155, United States
  • New Horizon Research Center
    Miami, Florida 33165, United States
  • South Broward Research LLC
    Miramar, Florida 33027, United States
  • West Orange Endocrinology
    Ocoee, Florida 34761, United States
  • Optimal Research Sites
    Orange City, Florida 32763, United States
  • Center for Diab,Obes & Metab
    Pembroke Pines, Florida 33024, United States
  • Javara Inc. / Privia Medical Group Georgia LLC
    Fayetteville, Georgia 30214, United States
  • Clinical Invest Special_Gurnee
    Gurnee, Illinois 60031, United States
  • Iowa Diabetes & Endo Res Ctr
    West Des Moines, Iowa 50266, United States
  • Cotton-Oneill Diabetes and End
    Topeka, Kansas 66606-2806, United States
  • AES Minneapolis DRS
    Richfield, Minnesota 55423, United States
  • Velocity Clin Res Gulfport
    Gulfport, Mississippi 39503, United States
  • AES St. Louis DRS
    St Louis, Missouri 63141, United States
  • Univ of Nebraska Medical CTR
    Omaha, Nebraska 68198-3020, United States
  • Velocity Clin Res Albuquerque
    Albuquerque, New Mexico 87107, United States
  • Albany Medical College
    Albany, New York 12203, United States
  • Carteret Medical Group
    Morehead City, North Carolina 28557, United States
  • Piedmont Healthcare/Research
    Statesville, North Carolina 28625, United States
  • Lillestol Research LLC
    Fargo, North Dakota 58104, United States
  • Triad Research Institute
    Norman, Oklahoma 73072, United States
  • Circuit Clinical - PMSI
    Pottstown, Pennsylvania 19464, United States
  • Clinical Res Collaborative
    Cumberland, Rhode Island 02864, United States
  • Velocity Clin Res Providence
    East Greenwich, Rhode Island 02818, United States
  • Velocity Clin Res Gaffney
    Gaffney, South Carolina 29340, United States
  • Holston Medical Group
    Kingsport, Tennessee 37660, United States
  • Clinical Research Associates
    Nashville, Tennessee 37203, United States
  • Velocity Clin Res Austin
    Austin, Texas 78759, United States
  • Synexus Clin Res Dallas
    Dallas, Texas 75234, United States
  • UT Southwestern Med Center
    Dallas, Texas 75390, United States
  • JCCT- Juno NW Houston
    Houston, Texas 77040, United States
  • Synergy Groups Medical
    Houston, Texas 77061, United States
  • PlanIt Research, PLLC
    Houston, Texas 77079, United States
  • Sante Clinical Research
    Kerrville, Texas 78028, United States
  • Aeres Clinical Research
    Laredo, Texas 78041, United States
  • Biopharma Informatic, LLC
    McAllen, Texas 78503, United States
  • Privia Health Javara Clin Res.
    Stephenville, Texas 76401, United States
  • J.Lewis Research Inc
    Salt Lake City, Utah 84109, United States
  • Chrysalis Clinical Research
    St. George, Utah 84790, United States
  • TPMG Clinical Research
    Newport News, Virginia 23606, United States
  • Centro Médico CIMEL
    Lanús Este, Buenos Aires B1824KAJ, Argentina
  • Centro de Investigaciones Médicas Mar del Plata
    Mar del Plata, Buenos Aires B7600GNY, Argentina
  • Fundación CESIM
    Santa Rosa, La Pampa Province 6300, Argentina
  • Centro de Investigaciones Médicas Tucumán
    San Miguel de Tucuimán, Tucumán Province 4000, Argentina
  • IMOBA
    City of Buenos Aires, C1056ABH, Argentina
  • Centro de Investigaciones Metabólicas
    City of Buenos Aires, C1056ABI, Argentina
  • Instituto de Investigaciones Clinicas San Nicolás
    San Nicolás, B2900, Argentina
  • Paratus Clinical
    Bruce, Australian Capital Territory 2617, Australia
  • Hunter Diabetes Centre
    Merewether, New South Wales 2291, Australia
  • Austrials
    St Leonards, New South Wales 2065, Australia
  • Momentum Clinical Research St Leonards
    St Leonards, New South Wales 2065, Australia
  • Roger Chih Yu Chen
    Sydney, New South Wales 2148, Australia
  • Townsville University Hospital
    Douglas, Queensland 4814, Australia
  • Paratus Clinical
    Herston, Queensland 4006, Australia
  • Centro de Diabetes Curitiba
    Curitiba, Paraná 80810-040, Brazil
  • Núcleo de Pesquisa Clínica do Rio Grande do Sul Ltda.
    Porto Alegre, Rio Grande do Sul 90430-001, Brazil
  • CPQuali Pesquisa Clínica Ltda
    São Paulo, São Paulo 01228-000, Brazil
  • Hilltop Medical Clinic
    Surrey, British Columbia V4A 0C1, Canada
  • G.A. Research Associates Ltd.
    Moncton, New Brunswick E1G 1A7, Canada
  • Centricity Research Brampton Endocrinology
    Brampton, Ontario L6S 0C6, Canada
  • Centricity Research Etobicoke Endocrinology
    Etobicoke, Ontario M9R 4E1, Canada
  • Wharton Medical Clinic Clinical Trials (Hamilton)
    Hamilton, Ontario L8L 5G8, Canada
  • London Road Diagnostic Clinic and Medical Centre
    Sarnia, Ontario N7T 4X3, Canada
  • Diabetes Heart Research Centre
    Toronto, Ontario M6G 1M2, Canada
  • Ctr de recherche Clinique de Laval
    Laval, Quebec H7T 2P5, Canada
  • Alpha Recherche Clinique - Clinique de Levis
    Lévis, Quebec G6V 0C9, Canada
  • Centre Medical Acadie
    Montreal, Quebec H4N 2W2, Canada
  • Ctr de Med Metab de Lanaudiere
    Terrebonne, Quebec J6X 4P7, Canada
  • Diex Recherche Victoriaville
    Victoriaville, Quebec G6P 3Z8, Canada
  • Centre de Recherche Saint-Louis
    Québec, G1W 4R4, Canada
  • Herz- und Diabeteszentrum NRW - Bad Oeynhausen
    Bad Oeynhausen, 32545, Germany
  • Universitätsklinikum Essen - Klinik für Endokrinologie, Diabetologie und Stoffwechsel
    Essen, 45147, Germany
  • Praxis am Markt Dr. Becker
    Essen, 45355, Germany
  • Universitätsklinikum Freiburg - Innere Medizin II
    Freiburg im Breisgau, 79106, Germany
  • Wendisch - Dahl Hamburg - DZHW
    Hamburg, 22607, Germany
  • Medicover Neuroendokrinologie MVZ München
    München, 81667, Germany
  • MedicalCenter am Clemenshospital - Schwerpunktpraxis für Diabetologie und Ernährungsmedizin
    Münster, 48153, Germany
  • Zentrum für klinische Studien Allgäu Oberschwaben
    Wangen, 88239, Germany
  • Alexandra General Hospital, Therapeutic Clinic
    Athens, Attica 11528, Greece
  • General Hospital Venizeleio-Pananeio - Diabetic Clinic
    Heraklion, Crete 71409, Greece
  • Evangelismos Hospital
    Athens, 10676, Greece
  • Iatriko Athinon 'Palaiou Falirou'
    Athens, 17562, Greece
  • "Laiko" General Hospital of Athens
    Goudi/Athens, 11527, Greece
  • University General Hospital of Ioannina,Internal Medicine
    Ioannina, 45500, Greece
  • General Hospital of Thessaloniki 'G. Gennimatas
    Thessaloniki, 54635, Greece
  • 'Ippokrateio' General Hospital of Thessaloniki
    Thessaloniki, 54642, Greece

Showing the first 100 of 163 sites across 14 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisktrials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2024 to primary completion in Jun 2026, 18 months.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 18 months is close to that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2024
First posted
Aug 2, 2024
StartActual
Nov 5, 2024
Primary completionActual
Jun 2, 2026
CompletionActual
Jul 9, 2026
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06534411
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Aug 2, 2024
Start date
Nov 5, 2024
Primary completion
Jun 2, 2026
Completion
Jul 9, 2026
Last update
Oct 19, 2026

Study contacts

Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cagrilintide

Start the discussion